Johnson & Johnson $JNJ Stock Holdings Raised by JT Stratford LLC

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

JT Stratford LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.7% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,089 shares of the company's stock after purchasing an additional 6,813 shares during the period. Johnson & Johnson makes up about 1.6% of JT Stratford LLC's holdings, making the stock its 14th largest holding. JT Stratford LLC's holdings in Johnson & Johnson were worth $8,804,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Berkshire Asset Management LLC PA lifted its stake in Johnson & Johnson by 1.2% during the first quarter. Berkshire Asset Management LLC PA now owns 255,258 shares of the company's stock worth $39,733,000 after purchasing an additional 3,084 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its stake in Johnson & Johnson by 9.2% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 417,068 shares of the company's stock worth $69,167,000 after purchasing an additional 34,980 shares in the last quarter. Legacy Financial Advisors Inc. lifted its stake in Johnson & Johnson by 14.7% during the first quarter. Legacy Financial Advisors Inc. now owns 18,294 shares of the company's stock worth $3,034,000 after purchasing an additional 2,350 shares in the last quarter. Andina Capital Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $330,000. Finally, Texas Capital Bank Wealth Management Services Inc lifted its stake in Johnson & Johnson by 39.0% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 8,730 shares of the company's stock worth $1,448,000 after purchasing an additional 2,448 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $0.7890 during mid-day trading on Wednesday, reaching $178.5890. The stock had a trading volume of 9,028,878 shares, compared to its average volume of 8,462,277. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $430.10 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 2.26 and a beta of 0.41. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $180.61. The business has a 50 day simple moving average of $162.13 and a 200 day simple moving average of $158.73.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Morgan Stanley increased their target price on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.